

Supplementary Documents [IFRS]

Financial results for the first nine months of the fiscal year 2025 (FY2025)

Astellas Pharma Inc.

- Q3 YTD/FY2025 Financial Results
 - Nine months ended December 31, 2025
 - Three months ended December 31, 2025
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[Nine months ended December 31, 2025]

1. Consolidated Results (Full Basis)

	Unit: B¥				FY24 Full Year	Previous Forecast	Latest Forecast	Change from FY24
	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)				
Revenue	1,453.0	1,601.3	148.3	10.2%	1,912.3			
Cost of sales	272.3	314.8	42.4	15.6%	349.2			
Gross profit	1,180.7	1,286.6	105.9	9.0%	1,563.1			
SG&A expenses	631.7	625.6	-6.1	-1.0%	843.0			
XTANDI co-promotion fee in the United States	200.1	193.1	-7.0	-3.5%	252.6			
SG&A excl. the above	431.6	432.6	0.9	0.2%	590.5			
R&D expenses	29.7%	27.0%			30.9%			
Ratio to Revenue	251.4	218.9	-32.5	-12.9%	327.7			
Ratio to Revenue	17.3%	13.7%			17.1%			
Amortisation of intangible assets	104.2	100.2	-4.0	-3.8%	136.8			
Gain on divestiture of intangible assets	1.0	4.0	3.0	304.5%	1.0			
Share of profit (loss) of investments accounted for using equity method	-0.6	-1.6	-1.0	-	-0.3			
Other income	4.4	25.4	21.0	475.4%	20.3			
Net foreign exchange gains	-	7.6	7.6	-	-			
Fair value remeasurements on contingent consideration	2.3	16.9	14.6	641.0%	16.7			
Other expenses	220.6	35.8	-184.8	-83.8%	235.8			
Impairment losses for intangible assets	181.2	22.6	-158.5	-87.5%	187.6			
Restructuring costs	10.3	6.5	-3.8	-37.1%	15.5			
Net foreign exchange losses	16.1	-	-16.1	-	18.6			
Fair value remeasurements on contingent consideration	4.0	0.3	-3.7	-93.4%	-			
Operating profit	-22.5	333.9	356.4	-	41.0			
Ratio to Revenue	-1.5%	20.9%			2.1%			
Finance income	6.9	5.7	-1.2	-17.5%	7.9			
Finance expenses	13.8	11.0	-2.7	-19.8%	17.7			
Profit before tax	-29.3	328.6	357.9	-	31.2			
Income tax expense	-5.2	80.6	85.8	-	-19.5			
Profit	-24.1	248.0	272.1	-	50.7			
Comprehensive income	30.6	384.2	353.6	-	48.9			

2. Consolidated Results (Core Basis)

Unit: B¥

	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)
Revenue	1,453.0	1,601.3	148.3	10.2%
Cost of sales	272.3	314.8	42.4	15.6%
Gross profit	1,180.7	1,286.6	105.9	9.0%
SG&A expenses	631.7	625.6	-6.1	-1.0%
XTANDI co-promotion fee in the United States	200.1	193.1	-7.0	-3.5%
SG&A excl. the above	431.6	432.6	0.9	0.2%
Ratio to Revenue	29.7%	27.0%		
R&D expenses	251.4	218.9	-32.5	-12.9%
Ratio to Revenue	17.3%	13.7%		
Operating profit	297.5	442.1	144.5	48.6%
Ratio to Revenue	20.5%	27.6%		
Finance income	6.9	5.7	-1.2	-17.5%
Finance expenses	13.8	11.0	-2.7	-19.8%
Profit before tax	290.7	436.7	146.0	50.2%
Income tax expense	67.6	105.1	37.5	55.4%
Profit	223.1	331.6	108.6	48.7%

	Previous Forecast	Latest Forecast	Change from FY24
	FY25 Full Year	FY25 Full Year	Change (%)
FY24 Full Year	1,912.3	2,100.0	9.8%
2,030.0	349.2	406.0	16.3%
387.0	1,563.1	1,694.0	8.4%
1,643.0	843.0	859.0	1.9%
245.0	252.6	259.0	2.6%
586.0	590.5	600.0	1.6%
30.9%	28.9%	28.6%	
327.7	322.0	315.0	-3.9%
17.1%	15.9%	15.0%	
392.4	490.0	520.0	32.5%
20.5%	24.1%	24.8%	
7.9			
17.7			
382.6			
87.0			
295.7	365.0	385.0	30.2%

3. Exchange Rate

Unit: ¥

	FY24 APR. - DEC.Ave.	FY25 APR. - DEC.Ave.	FY24 End	FY25 Q3 End
USD/Yen	152	149	150	157
EUR/Yen	165	172	162	184

	Previous Forecasts	Latest Forecast
	FY25 Full Year	FY25 Full Year
FY24 Full Year	152	150
164	170	174

* Fx impacts: Revenue -2.2 billion yen and Core operating profit +4.2 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY24 APR. - DEC.			FY25 APR. - DEC.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	1,453.0	-	1,453.0	1,601.3	-	1,601.3
Cost of sales	272.3	-	272.3	314.8	-	314.8
Gross profit	1,180.7	-	1,180.7	1,286.6	-	1,286.6
SG&A expenses	631.7	-	631.7	625.6	-	625.6
R&D expenses	251.4	-	251.4	218.9	-	218.9
Amortisation of intangible assets *	104.2	-104.2	-	100.2	-100.2	-
Gain on divestiture of intangible assets *	1.0	-1.0	-	4.0	-4.0	-
Share of profit (loss) of investments accounted for using equity method *	-0.6	0.6	-	-1.6	1.6	-
Other income *	4.4	-4.4	-	25.4	-25.4	-
Other expenses *	220.6	-220.6	-	35.8	-35.8	-
Operating profit	-22.5	320.0	297.5	333.9	108.2	442.1
Finance income	6.9	-	6.9	5.7	-	5.7
Finance expenses	13.8	-	13.8	11.0	-	11.0
Profit before tax	-29.3	320.0	290.7	328.6	108.2	436.7
Income tax expense	-5.2	72.8	67.6	80.6	24.5	105.1
Profit	-24.1	247.2	223.1	248.0	83.7	331.6

* 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets', 'Share of profit (loss) of investments accounted for using equity method', 'Other income' and 'Other expenses' are excluded from Core basis results. "Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

		Unit: B¥				Change from FY24
		FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)	
Revenue		1,453.0	1,601.3	148.3	10.2%	
	Japan	205.7	223.1	17.3	8.4%	
	Ratio to Revenue	14.2%	13.9%			
	United States	665.1	700.7	35.6	5.3%	
	Ratio to Revenue	45.8%	43.8%			
	Established Markets	363.8	418.0	54.2	14.9%	
	Ratio to Revenue	25.0%	26.1%			
	China	58.1	77.4	19.3	33.3%	
	Ratio to Revenue	4.0%	4.8%			
	International Markets	152.2	174.7	22.5	14.8%	
	Ratio to Revenue	10.5%	10.9%			

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

6. Investment in Property, Plant and Equipment

Depreciation/Amortisation

		Unit: B¥				Disclosed Oct 2025
		FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)	
Investment in Property, Plant and Equipment		41.5	32.5	-9.0	-21.7%	
Depreciation (PP&E)		33.9	32.5	-1.4	-4.1%	
Amortisation of Intangible Assets (incl. software, etc.)		117.5	111.7	-5.8	-4.9%	

- Investment in Property, Plant and Equipment does not include right-of-use asset.

7. Sales of major brands

1) Global

Unit: B¥

	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)
PADCEV	117.0	162.6	45.6	39.0%
Japan	8.7	15.8	7.2	82.4%
United States	80.5	91.2	10.7	13.3%
Established Markets	23.6	38.7	15.1	63.8%
China	0.3	9.6	9.3	-
International Markets	3.9	7.3	3.4	88.0%
IZERVAY	44.4	55.8	11.4	25.6%
United States	44.4	55.8	11.3	25.5%
VYLOY	4.9	46.1	41.1	831.4%
Japan	3.1	10.4	7.3	235.3%
United States	1.1	21.0	19.8	-
Established Markets	0.7	7.6	7.0	-
China	-	6.1	6.1	-
International Markets	-	0.9	0.9	-
VEOZAH	24.4	35.2	10.8	44.0%
United States	22.3	31.0	8.8	39.4%
Established Markets	2.0	3.4	1.4	67.4%
International Markets	0.1	0.7	0.5	357.4%
XOSPATA	53.1	53.5	0.4	0.8%
Japan	3.7	4.0	0.3	8.7%
United States	27.3	24.1	-3.3	-12.0%
Established Markets	13.7	16.8	3.1	22.6%
China	4.5	3.3	-1.2	-26.6%
International Markets	3.8	5.3	1.5	38.9%
XTANDI	703.1	732.2	29.1	4.1%
Japan	44.3	49.8	5.5	12.4%
United States	389.3	376.8	-12.5	-3.2%
Established Markets	198.0	217.2	19.1	9.7%
China	11.1	17.3	6.2	55.5%
International Markets	60.3	71.1	10.8	18.0%
BETANIS/MYRBETRIQ/BETMIGA	124.5	132.5	8.0	6.4%
PROGRAF	155.6	158.8	3.2	2.1%

FY24 Full Year	FY25 Full Year
164.1	210.0
12.6	22.0
109.1	120.0
32.7	46.0
3.9	12.0
5.7	9.0
58.3	80.0
58.3	80.0
12.2	60.0
5.2	15.0
4.9	28.0
2.2	8.0
-	6.0
-	1.0
33.8	50.0
30.8	42.0
2.7	6.0
0.3	1.0
68.0	70.0
4.7	5.0
35.0	33.0
18.9	21.0
3.9	5.0
5.5	7.0
912.3	938.0
57.9	64.0
491.7	477.0
262.1	281.0
16.3	22.0
84.3	94.0
170.0	163.0
201.0	196.0

Full-year forecast for the brands are as of Oct 2025

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by region

Full-year forecast for the brands are as of Oct 2025

(1) Japan

	Unit: B¥			
	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)
Revenue	205.7	223.1	17.3	8.4%
PADCEV	8.7	15.8	7.2	82.4%
VYLOY	3.1	10.4	7.3	235.3%
XOSPATA	3.7	4.0	0.3	8.7%
XTANDI	44.3	49.8	5.5	12.4%
BETANIS	19.2	17.3	-1.9	-9.9%
PROGRAF (Including GRACEPTOR)	17.2	14.3	-2.9	-16.8%
SUGLAT [Family]	20.7	18.5	-2.2	-10.6%
BLINCYTO	10.5	12.0	1.5	14.4%
EVENITY	42.9	54.8	11.9	27.7%
FY24 Full Year	267.0			
FY25 Full Year	281.0			
	12.6			
	22.0			
	5.2			
	15.0			
	4.7			
	57.9			
	24.6			
	23.0			
	21.2			
	18.0			
	26.4			
	24.0			
	13.4			
	57.9			

(2) United States

	Unit: M\$			
	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)
Revenue	4,362	4,711	348	8.0%
PADCEV	528	613	85	16.1%
IZERVAY	292	375	84	28.7%
VYLOY	8	141	133	-
VEOZAH	146	209	63	42.9%
XOSPATA	179	162	-18	-9.8%
XTANDI	2,554	2,533	-20	-0.8%
MYRBETRIQ	284	299	15	5.4%
CRESEMBA	231	267	36	15.7%
FY24 Full Year	5,683			
FY25 Full Year	6,210			
	716			
	830			
	382			
	550			
	32			
	190			
	202			
	290			
	230			
	3,225			
	3,290			
	410			
	380			
	310			

(3) Established Markets

	Unit: M€			
	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)
Revenue	2,209	2,432	223	10.1%
PADCEV	143	225	82	57.0%
VYLOY	4	44	40	969.9%
VEOZA	12	20	7	60.4%
XOSPATA	83	98	15	17.5%
XTANDI	1,203	1,264	61	5.1%
BETMIGA	282	317	36	12.7%
PROGRAF	342	348	5	1.6%
FY24 Full Year	2,967			
FY25 Full Year	3,110			
	200			
	270			
	13			
	50			
	17			
	115			
	120			
	1,602			
	1,650			
	382			
	390			
	450			

- Established Markets: Europe, Canada, etc.

(4) China

Full-year forecast for the brands are as of Oct 2025

	Unit: B¥			
	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)
Revenue	58.1	77.4	19.3	33.3%
PADCEV	0.3	9.6	9.3	-
VYLOY	-	6.1	6.1	-
XOSPATA	4.5	3.3	-1.2	-26.6%
XTANDI	11.1	17.3	6.2	55.5%
PROGRAF	33.3	32.8	-0.5	-1.5%
FY24 Full Year	78.3			
FY25 Full Year	94.0			
	3.9			
	12.0			
	6.0			
	3.9			
	5.0			
	16.3			
	22.0			
	40.0			

- China: China, Hong Kong

(5) International Markets

	Unit: B¥			
	FY24 APR. - DEC.	FY25 APR. - DEC.	Change	Change (%)
Revenue	152.2	174.7	22.5	14.8%
PADCEV	3.9	7.3	3.4	88.0%
VYLOY	-	0.9	0.9	-
VEOZA	0.1	0.7	0.5	357.4%
XOSPATA	3.8	5.3	1.5	38.9%
XTANDI	60.3	71.1	10.8	18.0%
BETMIGA	14.4	15.4	1.1	7.6%
PROGRAF	40.9	43.9	3.0	7.3%
FY24 Full Year	203.5			
FY25 Full Year	219.0			
	5.7			
	9.0			
	1.0			
	0.3			
	1.0			
	5.5			
	7.0			
	84.3			
	94.0			
	18.8			
	19.0			
	51.4			
	52.0			

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

8. Consolidated statements of financial position

Unit: B¥

	FY24 End	FY25 Q3 End	Change
Assets	3,339.5	3,603.9	264.4
Non-current assets	2,138.2	2,162.6	24.4
Property, plant and equipment	328.9	352.4	23.5
Goodwill	415.2	436.1	20.9
Intangible assets	1,123.7	1,052.0	-71.7
Trade and other receivables	18.5	18.1	-0.3
Investments accounted for using equity method	19.0	19.5	0.5
Deferred tax assets	98.1	130.8	32.7
Other financial assets	106.2	121.5	15.3
Other non-current assets	28.6	32.2	3.6
Current assets	1,201.3	1,441.3	239.9
Inventories	297.3	330.0	32.7
Trade and other receivables	632.5	777.8	145.2
Income tax receivable	13.7	14.3	0.6
Other financial assets	29.9	23.6	-6.3
Other current assets	39.2	41.3	2.1
Cash and cash equivalents	188.4	254.3	65.9
Assets held for sale	0.4	-	-0.4

Unit: B¥

	FY24 End	FY25 Q3 End	Change
Equity and Liabilities	3,339.5	3,603.9	264.4
Equity	1,513.3	1,764.9	251.6
Equity attributable to owners of the parent	1,513.3	1,763.1	249.9
Share capital	103.0	103.0	-
Capital surplus	185.3	184.6	-0.7
Treasury shares	-37.5	-35.1	2.4
Retained earnings	740.9	855.0	114.1
Other components of equity	521.6	655.6	134.1
Non-controlling interest	-	1.7	1.7
Liabilities	1,826.3	1,839.0	12.8
Non-current liabilities	764.7	514.5	-250.2
Bonds and borrowings	564.9	320.0	-244.9
Income tax payable	3.2	4.5	1.3
Deferred tax liabilities	5.4	11.0	5.7
Retirement benefit liabilities	22.7	23.2	0.5
Provisions	8.1	5.3	-2.8
Other financial liabilities	106.8	92.3	-14.4
Other non-current liabilities	53.6	58.1	4.5
Current liabilities	1,061.6	1,324.6	263.0
Bonds and borrowings	266.5	405.3	138.7
Trade and other payables	187.8	182.0	-5.9
Income tax payable	34.5	61.0	26.5
Provisions	17.3	26.0	8.7
Other financial liabilities	20.1	24.6	4.4
Other current liabilities	535.3	625.8	90.5

[Three months ended December 31, 2025]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue	505.8	6.9%	524.3	13.4%	571.2	10.4%
Cost of sales	94.8	4.1%	105.5	27.6%	114.4	16.1%
Gross profit	411.0	7.6%	418.8	10.3%	456.8	9.1%
SG&A expenses	197.0	-4.8%	206.8	3.7%	221.8	-1.6%
XTANDI co-promotion fee in the United States	62.9	2.1%	64.3	-0.3%	65.9	-11.1%
SG&A excl. the above	134.1	-7.7%	142.6	5.5%	155.9	3.1%
R&D expenses	26.5%		27.2%		27.3%	
Ratio to Revenue	71.7	-17.4%	71.6	-16.3%	75.6	-4.4%
Ratio to Revenue	14.2%		13.7%		13.2%	
Amortisation of intangible assets	32.8	-6.4%	32.7	-4.4%	34.7	-0.7%
Gain on divestiture of intangible assets	3.7	306.9%	0.3	-	0.0	-94.1%
Share of profit (loss) of investments accounted for using equity method	-1.6	-	0.0	-	-0.0	-
Other income	4.4	-10.8%	0.8	-	20.2	-
Net foreign exchange gains	-	-	0.5	-	7.1	-
Fair value remeasurements on contingent consideration	4.0	97.7%	0.0	-93.2%	12.8	-
Other expenses	21.3	105.5%	4.0	-75.6%	10.4	-94.6%
Impairment losses for intangible assets	13.6	-	2.8	-	6.3	-96.5%
Restructuring costs	2.8	8.7%	2.1	-59.9%	1.6	-35.9%
Net foreign exchange losses	2.3	-	-2.3	-	-	-
Fair value remeasurements on contingent consideration	0.7	-87.0%	0.4	-	-0.9	-
Operating profit	94.6	86.8%	104.7	143.3%	134.5	-
Ratio to Revenue	18.7%		20.0%		23.5%	
Finance income	1.7	-61.5%	2.2	297.5%	1.9	-7.7%
Finance expenses	5.9	31.2%	2.7	-46.6%	2.4	-42.1%
Profit before tax	90.4	79.1%	104.2	170.3%	134.0	-
Income tax expense	22.0	70.6%	25.0	846.6%	33.6	-
Profit	68.4	82.0%	79.2	120.6%	100.3	-
Comprehensive income	34.9	-76.7%	129.7	-	219.6	652.1%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue	505.8	6.9%	524.3	13.4%	571.2	10.4%
Cost of sales	94.8	4.1%	105.5	27.6%	114.4	16.1%
Gross profit	411.0	7.6%	418.8	10.3%	456.8	9.1%
SG&A expenses	197.0	-4.8%	206.8	3.7%	221.8	-1.6%
XTANDI co-promotion fee in the United States	62.9	2.1%	64.3	-0.3%	65.9	-11.1%
SG&A excl. the above	134.1	-7.7%	142.6	5.5%	155.9	3.1%
R&D expenses	26.5%		27.2%		27.3%	
Ratio to Revenue	71.7	-17.4%	71.6	-16.3%	75.6	-4.4%
Ratio to Revenue	14.2%		13.7%		13.2%	
Operating profit	142.3	61.1%	140.4	48.1%	159.4	39.3%
Ratio to Revenue	28.1%		26.8%		27.9%	
Finance income	1.7	-61.5%	2.2	297.5%	1.9	-7.7%
Finance expenses	5.9	31.2%	2.7	-46.6%	2.4	-42.1%
Profit before tax	138.0	56.6%	139.8	54.9%	158.9	41.5%
Income tax expense	33.3	58.8%	33.1	98.7%	38.7	29.0%
Profit	104.7	56.0%	106.7	45.0%	120.2	46.0%

3. Revenue by Region

Unit: B¥

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
	505.8	6.9%	524.3	13.4%	571.2	10.4%
Revenue	Japan	68.9	3.4%	74.0	10.7%	80.1
	Ratio to Revenue	13.6%		14.1%		11.0%
	United States	224.7	6.0%	232.4	12.2%	243.5
	Ratio to Revenue	44.4%		44.3%		42.6%
	Established Markets	128.8	6.4%	136.1	14.4%	153.1
	Ratio to Revenue	25.5%		26.0%		26.8%
China		29.4	57.8%	20.3	6.8%	27.6
	Ratio to Revenue	5.8%		3.9%		4.8%
International Markets		53.2	2.3%	58.3	21.5%	63.2
	Ratio to Revenue	10.5%		11.1%		11.1%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

4. Investment in Property,Plant and Equipment

Unit: B¥

Depreciation/Amortisation	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
	4.8	-64.1%	12.1	-20.2%	15.5	21.2%
Investment in Property, Plant and Equipment	11.1	2.2%	10.7	-6.3%	10.7	-7.9%
Depreciation (PP&E)						
Amortisation of Intangible Assets (incl. software, etc.)	36.7	-6.9%	36.6	-5.2%	38.4	-2.8%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major brands

1) Global

Unit: B¥

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
PADCEV	55.5	44.6%	46.9	26.9%	60.1	44.6%
Japan	5.1	102.3%	5.0	107.8%	5.7	52.5%
United States	31.7	16.7%	28.7	10.4%	30.8	12.6%
Established Markets	9.5	26.1%	10.6	42.3%	18.6	115.4%
China	7.4	-	-0.2	-	2.3	-
International Markets	1.8	62.6%	2.8	171.8%	2.7	54.1%
IZERVAY	15.9	25.2%	18.2	18.3%	21.7	32.7%
United States	15.9	25.2%	18.2	18.3%	21.6	32.6%
VYLOY	14.0	-	12.5	-	19.5	425.6%
Japan	3.1	791.2%	3.3	274.4%	4.0	114.4%
United States	5.9	-	6.3	-	8.8	664.0%
Established Markets	1.7	-	2.7	-	3.3	390.5%
China	3.3	-	-0.1	-	2.9	-
International Markets	0.1	-	0.3	-	0.5	-
VEOZAH	9.6	45.6%	13.3	62.0%	12.3	27.7%
United States	8.6	39.7%	11.9	59.2%	10.6	22.2%
Established Markets	0.9	107.2%	1.2	69.4%	1.3	46.5%
International Markets	0.1	861.7%	0.2	366.6%	0.3	258.9%
XOSPATA	17.0	-1.9%	17.5	-0.3%	19.0	4.3%
Japan	1.3	3.8%	1.2	7.2%	1.5	14.9%
United States	7.4	-17.8%	7.9	-10.5%	8.8	-8.0%
Established Markets	5.6	20.8%	5.8	29.7%	5.4	17.4%
China	1.0	-26.6%	1.0	-41.3%	1.4	-11.0%
International Markets	1.7	57.0%	1.5	9.0%	2.0	55.8%
XTANDI	233.0	3.9%	244.0	7.3%	255.2	1.5%
Japan	15.9	7.1%	16.2	16.6%	17.7	13.7%
United States	122.6	2.4%	125.2	-0.1%	129.0	-10.5%
Established Markets	69.5	5.7%	71.8	8.8%	75.9	14.4%
China	4.8	58.3%	5.9	53.4%	6.6	55.4%
International Markets	20.2	-3.2%	24.8	35.9%	26.1	23.4%
BETANIS/MYRBETRIQ/BETMIGA	43.0	-6.8%	43.5	38.4%	46.0	-2.0%
PROGRAF	51.2	-4.9%	52.0	3.9%	55.6	7.6%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by region

(1) Japan

Unit: B¥

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue	68.9	3.4%	74.0	10.7%	80.1	11.0%
PADCEV	5.1	102.3%	5.0	107.8%	5.7	52.5%
VYLOY	3.1	791.2%	3.3	274.4%	4.0	114.4%
XOSPATA	1.3	3.8%	1.2	7.2%	1.5	14.9%
XTANDI	15.9	7.1%	16.2	16.6%	17.7	13.7%
BETANIS	5.7	-14.3%	5.5	-7.1%	6.2	-8.0%
PROGRAF (Including GRACEPTOR)	4.6	-27.4%	4.6	-18.2%	5.0	-2.1%
SUGLAT [Family]	6.3	-10.2%	5.9	-9.3%	6.3	-12.1%
BLINCYTO	3.5	8.2%	3.9	16.7%	4.7	17.5%
EVENITY	16.5	20.1%	17.8	30.1%	20.5	32.4%

(2) United States

Unit: M\$

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue	1,555	14.3%	1,576	13.4%	1,580	-2.0%
PADCEV	219	25.9%	194	11.4%	199	11.3%
IZERVAY	110	35.0%	124	20.2%	141	31.9%
VYLOY	41	-	43	-	57	662.8%
VEOZAH	59	50.7%	81	62.0%	69	20.8%
XOSPATA	51	-11.3%	54	-9.5%	57	-8.8%
XTANDI	848	10.4%	849	1.1%	836	-11.6%
MYRBETRIQ	107	-11.1%	104	163.4%	89	-28.8%
CRESEMBA	80	14.5%	92	19.1%	95	13.6%

(3) Established Markets

Unit: M€

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue	786	8.9%	790	8.7%	856	12.5%
PADCEV	58	29.1%	62	35.4%	105	99.2%
VYLOY	10	-	16	-	19	356.3%
VEOZA	5	112.1%	7	62.5%	7	34.2%
XOSPATA	34	23.7%	34	23.2%	30	5.9%
XTANDI	424	8.3%	417	3.3%	423	3.7%
BETMIGA	102	10.4%	102	12.3%	114	15.1%
PROGRAF	113	-1.1%	114	2.0%	121	3.9%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue	29.4	57.8%	20.3	6.8%	27.6	35.6%
PADCEV	7.4	-	-0.2	-	2.3	-
VYLOY	3.3	-	-0.1	-	2.9	-
XOSPATA	1.0	-26.6%	1.0	-41.3%	1.4	-11.0%
XTANDI	4.8	58.3%	5.9	53.4%	6.6	55.4%
PROGRAF	10.4	-7.5%	11.2	4.7%	11.3	-1.5%

- China: China, Hong Kong

(5) International Markets

Unit: B¥

	FY25					
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)
Revenue	53.2	2.3%	58.3	21.5%	63.2	21.1%
PADCEV	1.8	62.6%	2.8	171.8%	2.7	54.1%
VYLOY	0.1	-	0.3	-	0.5	-
VEOZA	0.1	861.7%	0.2	366.6%	0.3	258.9%
XOSPATA	1.7	57.0%	1.5	9.0%	2.0	55.8%
XTANDI	20.2	-3.2%	24.8	35.9%	26.1	23.4%
BETMIGA	5.0	1.3%	4.9	5.3%	5.6	16.2%
PROGRAF	14.9	3.7%	14.1	9.0%	14.9	9.4%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Feb 2026

Underlined items indicate changes from the previous announcement in Oct 2025.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Cisplatin-ineligible muscle-invasive bladder cancer (combo with pembrolizumab)	US <u>Approved (Nov 2025)</u> Europe <u>Filed (Nov 2025)</u> Japan <u>Filed (Jan 2026)</u> NCT03924895	In-house [Co-development with Pfizer]	
			Cisplatin-eligible muscle-invasive bladder cancer (combo with pembrolizumab)	P-III NCT04700124		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III NCT04027309	In-house	
			Post-chemotherapy maintenance acute myeloid leukemia	P-III		
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-II NCT05520567		
			Acute myeloid leukemia in pediatric patients	P-III NCT04293562		
			ALK-positive non-small cell lung cancer	P-I NCT07140016		
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with pembrolizumab and chemotherapy)	P-III NCT06901531	In-house (Ganymed)	

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
fezolinetant ESN364 (VEOZAH***)	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III NCT06812754 Japan P-III NCT06206408 NCT06206421	In-house (Ogeda)	
			Vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III NCT06440967		

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Oct 2025):

avacincaptad pegol: Removed the description of the approval in Japan for suppression of geographic atrophy growth in atrophic age-related macular degeneration in Sep 2025.

enfortumab vedotin: Approved in US in Nov 2025, Filed in Europe in Nov 2025 and Japan in Jan 2025 for cisplatin-ineligible muscle-invasive bladder cancer.

zolbetuximab: Discontinued the development for pancreatic adenocarcinoma because Phase 2 study did not meet its primary endpoint.

Programs with Focus Area approach

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
Immuno-oncology	ASP1570	Small molecule	DGKζ inhibitor	Cancer	P-I NCT05083481	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I NCT05365581 NCT07024615	Xencor [Discovered through collaborative research]	
	ASP1002	Antibody	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I NCT05719558	In-house	
Targeted Protein Degradation	setidegrasib ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I NCT05382559	In-house	
	ASP5834	Small molecule	Pan-KRAS degrader	Cancer	P-I NCT07094204	In-house	
Genetic regulation	resamirigene bilparvovec AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II NCT03199469	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-II NCT04174105	In-house (Audentes Therapeutics)	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I NCT03178149	In-house (Ocata Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Oct 2025):

ASP4396: Discontinued Phase 1 program for cancer.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase * CT information	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III NCT05621616	In-house	
roxadustat ASP1517/FG-4592	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III NCT05970172	Kyntra Bio	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate ASP5541/PRL-02	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-II NCT07005154	In-house (Propella Therapeutics)	
ASP546C/XNW27011	Antibody-drug conjugate (ADC)	Claudin 18.2-targeted ADC	Cancer	P-I NCT06792435	Evopoint Biosciences	Astellas has worldwide rights excluding China's mainland, Hong Kong, Macau, and Taiwan.
ASP5502	Small molecule	STING inhibitor	Primary Sjogren's syndrome	P-I NCT06544642	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Category	Program	Concept	Status*	Partner	Remarks
Digital health	BlueStar	Digital therapeutic for the management of diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
Drug-device combination	pudexacianinium chloride ASP5354	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
Implantable medical device	Akyva	Implantable device for overactive bladder	Early feasibility study	(iota Biosciences)	

* The list shows the most advanced stage if the stages are different depending on the region.